一、醫(yī)學(xué)科技創(chuàng)新中心簡(jiǎn)介
醫(yī)學(xué)科技創(chuàng)新中心(轉(zhuǎn)化醫(yī)學(xué)研究院)(簡(jiǎn)稱“科創(chuàng)中心”)是山東第一醫(yī)科大學(xué)(山東省醫(yī)學(xué)科學(xué)院)科技創(chuàng)新的“特區(qū)”,是體制改革的“創(chuàng)新試驗(yàn)田”,定位高端科研創(chuàng)新平臺(tái),以對(duì)標(biāo)國(guó)際一流的科研院所,打造學(xué)校使命定位、領(lǐng)域方向、科研任務(wù)、人才隊(duì)伍、體制機(jī)制方面獨(dú)一無二、不可替代的核心競(jìng)爭(zhēng)力?苿(chuàng)中心建有大型儀器設(shè)備共享平臺(tái)、公共技術(shù)服務(wù)平臺(tái)、生物安全防護(hù)三級(jí)(P3)實(shí)驗(yàn)室、大型生物樣本庫(kù)等。其中大型儀器設(shè)備共享平臺(tái)設(shè)有省內(nèi)最大的電鏡中心、光學(xué)顯微平臺(tái)、分析測(cè)試平臺(tái)、流式細(xì)胞平臺(tái)、蛋白分析平臺(tái)、實(shí)驗(yàn)動(dòng)物平臺(tái),可滿足科研人員在不同研究領(lǐng)域的應(yīng)用需求;公共技術(shù)服務(wù)平臺(tái)設(shè)有分子生物學(xué)技術(shù)平臺(tái)、細(xì)胞生物學(xué)技術(shù)平臺(tái)、病理學(xué)技術(shù)平臺(tái)、實(shí)驗(yàn)動(dòng)物研究平臺(tái)、藥學(xué)實(shí)驗(yàn)室等子平臺(tái),配有開展實(shí)驗(yàn)所需全套設(shè)備,滿足科研人員對(duì)實(shí)驗(yàn)技術(shù)的需求。
科創(chuàng)中心實(shí)施Principal Investigator(PI)負(fù)責(zé)制,充分發(fā)揮高層次人才的引領(lǐng)作用,目前已入駐100余位PI和臨床團(tuán)隊(duì),其中兩院院士2人,國(guó)家級(jí)人才18人,省部級(jí)人才40余人。自成立以來,科創(chuàng)中心圍繞免疫相關(guān)疾病、環(huán)境健康、納米轉(zhuǎn)化、醫(yī)工交叉等一系列關(guān)乎人民生命健康的關(guān)鍵研究方向,共承擔(dān)各級(jí)科研項(xiàng)目385項(xiàng),其中國(guó)家級(jí)科研項(xiàng)目160余項(xiàng),包括國(guó)家重點(diǎn)研發(fā)計(jì)劃、國(guó)家重大研究計(jì)劃等;在Cell、Cell Metabolism、Nature Communications、Nature Aging、PNAS等國(guó)際知名期刊發(fā)表高水平論文600余篇,涉及蛋白質(zhì)結(jié)構(gòu)、糖脂代謝、乳酸代謝、納米治療、癌癥以及自身免疫病等不同研究領(lǐng)域。
此外,科創(chuàng)中心積極構(gòu)建高端學(xué)術(shù)交流平臺(tái),已成功舉辦150余期高質(zhì)量學(xué)術(shù)活動(dòng),邀請(qǐng)兩院院士、國(guó)家杰青等60余位國(guó)家級(jí)人才開展學(xué)術(shù)講座。
為深入實(shí)施人才強(qiáng)校戰(zhàn)略,吸引和凝聚優(yōu)秀人才,誠(chéng)邀全球英才依托科創(chuàng)中心申報(bào)2025年海外優(yōu)青項(xiàng)目(新增批次)!
二、項(xiàng)目介紹
國(guó)家自然科學(xué)基金優(yōu)秀青年科學(xué)基金項(xiàng)目(海外)旨在吸引和鼓勵(lì)在自然科學(xué)、工程技術(shù)等方面已取得較好成績(jī)的海外優(yōu)秀青年學(xué)者(含非華裔外籍人才)回國(guó)(來華)工作,自主選擇研究方向開展創(chuàng)新性研究,促進(jìn)青年科學(xué)技術(shù)人才的快速成長(zhǎng),培養(yǎng)一批有望進(jìn)入世界科技前沿的優(yōu)秀學(xué)術(shù)骨干,為科技強(qiáng)國(guó)建設(shè)貢獻(xiàn)力量。
三、申報(bào)條件
1.遵守中華人民共和國(guó)法律法規(guī),具有良好的科學(xué)道德,自覺踐行新時(shí)代科學(xué)家精神;
2.出生日期在1985年1月1日(含)以后;
3.具有博士學(xué)位;
4.研究方向主要為自然科學(xué)、工程技術(shù)等;
5.在取得博士學(xué)位后至2025年9月15日前,一般應(yīng)在海外知名高校、科研機(jī)構(gòu)、企業(yè)研發(fā)機(jī)構(gòu)等獲得正式教學(xué)或者科研職位,且具有連續(xù)36個(gè)月以上工作經(jīng)歷;在海外取得博士學(xué)位且業(yè)績(jī)特別突出的,可適當(dāng)放寬工作年限要求(不適用于通過中外聯(lián)合培養(yǎng)方式取得海外博士學(xué)位的情況)。
在海外工作期間,同時(shí)擁有境內(nèi)帶薪酬職位的申請(qǐng)人,其境內(nèi)帶薪酬職位的工作年限不計(jì)入海外工作年限。
6.取得同行專家認(rèn)可的科研或技術(shù)等成果,且具有成為該領(lǐng)域?qū)W術(shù)帶頭人或杰出人才的發(fā)展?jié)摿Γ?/p>
7.申請(qǐng)人尚未全職回國(guó)(來華)工作,或者2024年1月1日以后回國(guó)(來華)工作。獲資助通知后須辭去海外工作并全職回國(guó)(來華)工作不少于3年。
四、限項(xiàng)要求
l 執(zhí)行國(guó)家科技人才計(jì)劃統(tǒng)籌銜接的相關(guān)要求。同層次國(guó)家科技人才計(jì)劃只能承擔(dān)一項(xiàng),不能逆層次申請(qǐng)。
l 對(duì)于已申請(qǐng)上半年國(guó)家海外優(yōu)青項(xiàng)目的申請(qǐng)人,因時(shí)間結(jié)點(diǎn)原因?qū)е虏环袭?dāng)時(shí)申請(qǐng)條件、但符合新增批次申請(qǐng)條件的,可申請(qǐng)新增批次項(xiàng)目;其他申請(qǐng)人不得在新增批次重復(fù)提交申請(qǐng)。
l 已申請(qǐng)2025年度其它同層次國(guó)家科技人才計(jì)劃的,不得在新增批次提交申請(qǐng)。
五、支持條件
對(duì)于以山東第一醫(yī)科大學(xué)為依托單位獲批國(guó)家自然科學(xué)基金優(yōu)秀青年科學(xué)基金項(xiàng)目(海外),全職來校(院)入職的項(xiàng)目負(fù)責(zé)人,可享受以下支持條件:
1.資源配置
聘任為教授/研究員,博士生導(dǎo)師,獨(dú)立PI,配備工作助手,提供博士后、研究生招生指標(biāo),支持組建高水平科研團(tuán)隊(duì),安排辦公實(shí)驗(yàn)用房。
2.薪酬待遇
①國(guó)家配套經(jīng)費(fèi)資助強(qiáng)度:100-300萬元,資助期限:3年。此外,學(xué)校提供具有競(jìng)爭(zhēng)力的年薪、購(gòu)房補(bǔ)貼和科研支持經(jīng)費(fèi),享受有關(guān)個(gè)人所得稅優(yōu)惠,同時(shí)為人才及隨行家屬提供回國(guó)(來華)就業(yè)前生活補(bǔ)貼;
②合同任務(wù)外標(biāo)志性成果獎(jiǎng)勵(lì)上不封頂;
③享受人才周轉(zhuǎn)公寓,協(xié)助解決配偶工作、子女入學(xué)及落戶等生活問題,同時(shí)山東第一醫(yī)科大學(xué)多家附屬醫(yī)院為人才提供一流的醫(yī)療保健服務(wù);
④符合條件的推薦申報(bào)省市各級(jí)相關(guān)支持項(xiàng)目,協(xié)助申領(lǐng)山東惠才卡,可享受出入境和居留、醫(yī)療保健、社會(huì)服務(wù)等29項(xiàng)綠色通道服務(wù)。
六、聯(lián)系方式
申請(qǐng)者請(qǐng)將個(gè)人簡(jiǎn)歷(包含個(gè)人基本信息,聯(lián)系方式,學(xué)習(xí)和工作經(jīng)歷,主要學(xué)術(shù)成果等)發(fā)送至郵箱:(kczx@sdfmu.edu.cn), 郵件主題請(qǐng)標(biāo)注為“海外優(yōu)青”。
聯(lián)系人:陳老師
聯(lián)系電話:0531-59556171;17627669715
Introduction
The Medical Science and Technology Innovation Center (Institute of Translational Medicine) (MSTIC) serves as a key research and innovation platform of Shandong First Medical University (Shandong Academy of Medical Sciences) and functions as a "testing ground" for technological advancements in medical science within Shandong Province. MSTIC is positioned as a high-end scientific research and innovation platform to benchmark world-class scientific research institutes and create a unique and irreplaceable core competitiveness in terms of mission positioning, field direction, scientific research tasks, talent team, and institutional mechanism. MSTIC houses several cutting-edge research facilities, including the High-End Instrument Sharing Platform, the Public Technology Service Platform, an Animal Biosafety Level 3 (ABSL-3) Laboratory, and a Large-Scale Biobank. The High-End Instrument Sharing Platform comprises six specialized sub-platforms, notably the largest Electron Microscope Centre in Shandong Province, along with the Optical Micro-Imaging Platform, Analytical Testing Platform, Flow Cytometry Platform, Protein Analysis Platform, and Experimental Animal Platform. The Public Technology Service Platform consists of experimental units dedicated to molecular biology technology platform, cell biology technology platform, pathology, experimental animal research platform, and pharmaceutical laboratory, all of which are equipped with state-of-the-art instrumentation essential for scientific research and education.
MSTIC actively implements “principal investigators (PI) system” to give full play to the leading role of talents. MSTIC has attracted world-class scientists and currently hosts over 100 PIs and clinical teams, including two teams led by the academicians of Chinese Academy of Sciences, 18 national-level talents, and over 40 provincial-level talents. Since its establishment, MSTIC has undertaken 385 research projects at various levels, including more than 160 national projects, such as the National Key Research and Development Program of China and the Major Research Plan of the National Natural Science Foundation of China. MSTIC has made significant contributions to scientific research, publishing more than 600 high-impact papers in top-tier international journals such as Cell, Cell Metabolism, Nature Communications, Blood, and PNAS. These publications span a broad range of research fields, including protein structure, lipid and lactate metabolism, nanotherapy, cancer research, and autoimmune diseases.
Additionally, MSTIC has established a high-end academic forum and has successfully hosted over 150 distinguished academic events, inviting more than 60 national-level experts, including academicians of the Chinese Academy of Sciences and Chinese Academy of Engineering and National Science Fund for Distinguished Young Scholars, to deliver academic presentations.
We sincerely invite outstanding academic talents to join us in building an international leading center dedicated to scientific and technological innovation, creating a better future!
Applicants (including postdoctoral fellows) are welcome to send the CVs (including personal information, contact details, educational and work experience, major academic achievements, etc.) to (kczx@sdfmu.edu.cn) marked as “Job Application”. Or contact Dr. Chen directly (Phone: +86-531-59556171).
信息來源于網(wǎng)絡(luò),如有變更請(qǐng)以原發(fā)布者為準(zhǔn)。
來源鏈接:
https://mp.weixin.qq.com/s/-Uoi_wi2aN-3fgNyaBWEBQ
為防止簡(jiǎn)歷投遞丟失請(qǐng)抄送一份至:boshijob@126.com(郵件標(biāo)題格式:應(yīng)聘職位名稱+姓名+學(xué)歷+專業(yè)+中國(guó)博士人才網(wǎng))
中國(guó)-博士人才網(wǎng)發(fā)布
聲明提示:凡本網(wǎng)注明“來源:XXX”的文/圖等稿件,本網(wǎng)轉(zhuǎn)載出于傳遞更多信息及方便產(chǎn)業(yè)探討之目的,并不意味著本站贊同其觀點(diǎn)或證實(shí)其內(nèi)容的真實(shí)性,文章內(nèi)容僅供參考。